LG completes phase 3 trial for sustained release recombinant human growth hormone

Published: 2009-06-16 06:59:00

Updated: 2009-06-16 06:59:00

LG Life Sciences Ltd., a Korean pharmaceutical manufacturer, said on June 11 that it has successfully completed phase 3, placebo-controlled six month efficacy and safety data in adults with growth hormone deficiency (GHD) for LB03002, a once-a-week, sustained release recombinant human growth horm...

Fees

- Email service daily and homepage access.

$300 per month. ($3,240 per year)
5 Email holders per each company.
Anual contract base.

Latest News

Which are outstanding tetravalent vaccines even for the young?

Disease treated the most with clinical trial drugs is respiratory disorder like lung cancer

Who will be the next Pharmaceutical Safety Bureau Director?

Celltrion completes clinical trials for Remsima SC for European approval

Sales listed pharmas made in the first half of the year

TOP

BACK